Free shipping on all orders over $ 500

Daclatasvir dihydrochloride

Cat. No. M3693

All AbMole products are for research use only, cannot be used for human consumption.

Daclatasvir dihydrochloride Structure
Synonym:

BMS790052 dihydrochloride

Size Price Availability Quantity
5mg USD 44  USD44 In stock
10mg USD 52  USD52 In stock
50mg USD 65  USD65 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Daclatasvir (DCV) is a potent hepatitis C virus (HCV) NS5A replication complex inhibitor with pangenotypic (1-6) activity in vitro. Daclatasvir inhibits the HCV nonstructural protein NS5A.Recent research suggests that it targets two steps of the viral replication process, enabling rapid decline of HCV RNA.Twelve or 16 weeks of treatment with daclatasvir, in combination with peginterferon alfa-2a and ribavirin, is well tolerated and effective therapy for patients with HCV genotype 2 or 3 infections. Daclatasvir-containing regimens could reduce the duration of therapy for these patients. Daclatasvir plus asunaprevir provided high sustained virological response rates in treatment-naive, non-responder, and ineligible, intolerant, or ineligible and intolerant patients, and was well tolerated in patients with HCV genotype 1b infection.

Chemical Information
Molecular Weight 811.80
Formula C40H52Cl2N8O6
CAS Number 1009119-65-6
Solubility (25°C) DMSO 148 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Garimella T, et al. J Int AIDS Soc. Evaluation of drug-drug interaction between daclatasvir and methadone or buprenorphine/naloxone.

[2] Nettles JH, et al. J Med Chem. Asymmetric Binding to NS5A by Daclatasvir (BMS-790052) and Analogs Suggests Two Novel Modes of HCV Inhibition.

[3] Dore GJ, et al. Gastroenterology. Daclatasvir plus Peginterferon and Ribavirin is Non-inferior to Peginterferon and Ribavirin Alone, and Reduces Duration of Treatment for HCV Genotype 2 or 3 Infection.

[4] Manns M, et al. Lancet. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.

Related HCV Protease Products
Telaprevir

Telaprevir (VX-950) is a novel hepatitis C virus (HCV) NS3-4A protease inhibitor with IC50 of < 0.2 μM.

BMS-790052

BMS-790052 (Daclatasvir) is a first-in-class, nonstructural protein 5A (NS5A) replication complex inhibitor with an EC50 of 9-50 pM.

(R)-Nepicastat hydrochloride

(R)-Nepicastat hydrochloride, the R-enantiomer of Nepicastat hydrochloride, is a potent and selective inhibitor with IC50 of 25.1 nM and 18.3 nM for bovine and human dopamine-β-hydroxylase, with negligible affinity for twelve other enzymes and thirteen neurotransmitter receptors.

Elbasvir

Elbasvir (MK-8742) is a hepatitis C virus nonstructural protein 5A (HCV NS5A) replication complex inhibitor, with EC50s of 4, 3 and 3 nM against genotype 1a, 1b, and 2a, respectively.

Dasabuvir (ABT-333)

ABT-333 is a nonnucleoside NS5B polymerase inhibitor for the treatment of HCV infection.

  Catalog
Abmole Inhibitor Catalog




Keywords: Daclatasvir dihydrochloride, BMS790052 dihydrochloride supplier, HCV Protease, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.